Hubbry Logo
PATH (global health organization)PATH (global health organization)Main
Open search
PATH (global health organization)
Community hub
PATH (global health organization)
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
PATH (global health organization)
PATH (global health organization)
PATH (global health organization)
View on Wikipedia
from Wikipedia

PATH (formerly known as the Program for Appropriate Technology in Health) is an international, nonprofit global health organization.[2] PATH is based in Seattle with 1,600 employees in more than 70 countries around the world. Its president and CEO is Nikolaj Gilbert, who is also the Managing Director and CEO of Foundations for Appropriate Technologies in Health (FATH), PATH's Swiss subsidiary. PATH focuses on six platforms: vaccines, drugs, diagnostics, devices, system, and service innovations.

Key Information

History

[edit]

Founded in 1977 as the Program for the Introduction and Adaptation of Contraceptive Technology with a focus on family planning, PATH soon broadened its purpose to work on a wide array of emerging and persistent global health issues in the areas of health technologies, maternal health, child health, reproductive health, vaccines and immunization, and emerging and epidemic diseases such as HIV, malaria, tuberculosis, and COVID-19.

In 2000, PATH had 300 employees and an annual budget of $60 million. In 2020, this increased to 1,600 employees and a budget of $323 million.[3]

Developed technologies

[edit]

Vaccine and pharmaceutical technologies

[edit]

PATH collaborated with the World Health Organization starting in 1979 to develop the vaccine vial monitor, a small sticker that adheres to a vaccine vial and changes color as the vaccine is exposed to heat over time. The sticker shows when a vaccine has reached its preset temperature limit and can no longer be safely used. It took over thirty years until 2007 for the widespread adoption of this technology by vaccine manufacturers.[4] UNICEF requires these monitors on all vaccines it purchases.[5]

PATH also developed the Uniject injection system. The single-dose, autodisabling injection system consists of a needle attached to a small bubble of plastic that is prefilled with medication. The system is designed to prevent disease transmission and requires low training to administer vaccine and other drugs safely, intended for remote villages.[6]

Nutrition

[edit]

Developed by Bon Dente International, Ultra Rice is a manufactured grain owned by PATH. Designed to resemble the texture and appearance of regular rice, it is a micronutrient fortified grain that can be mixed with rice to reduce malnutrition in countries where rice is a staple food.[7] The micronutrients include zinc, folic acid and iron, and it is capable of reducing the incidence of anemia and infant (6-24 month old) mortality in low-income populations. It is typically mixed with regular rice at a 1:100 ratio. Ultra Rice has been produced and tested in several countries, including Brazil, Burundi, and India, where it has been served in school-lunch programs.[8][9] Starting in 2010, PATH distributed Ultra Rice to Cambodia through food assistance programs and for further research, for which it now has over thirty studies. The results showed that fortified rice was well accepted by children, parents and teachers and consumption of it was similar or better than normal rice.[10] In 2012, PATH entered a business partnership in Brazil with a commercial rice producer to sell Ultra Rice mixed in with regular rice at supermarkets.[11]

Sexual and reproductive health

[edit]

PATH technologies address sexual and reproductive health include:

  • The careHPV test, developed in conjunction with Qiagen as the first molecular diagnostic to screen for human papillomavirus (HPV)—the most common cause of cervical cancer—in clinics in low-resource settings. China's State Food and Drug Administration approved the test for sale beginning in January 2013, followed by India and other emerging markets.[12] The test is designed specifically for use in clinics that lack reliable clean water or electricity.
  • The SILCS diaphragm, a "one size fits most" contraceptive device. The device differs from traditional latex diaphragms in that it is made of silicone instead of latex, is designed to hold up to extreme temperatures and poor storage conditions common in developing countries, and will not require a doctor's fitting.[13]
  • The Woman's Condom, a female condom designed to be easier to use effectively, less noisy and more comfortable other female condoms.[14] PATH transferred production of the condom to Dahua Medical Apparatus Company in China in 2008. The condom has received regulatory approvals in China and the European Union and became commercially available in China in late 2011.[15]

Water and sanitation

[edit]

PATH looks at ways to improve water quality in developing countries, including helping companies develop low-cost filters, gadgets, and other water-treatment products to stimulate a commercial market and keep prices low.[16] Most recently, PATH partnered with Splash! to develop and test a handwashing station for use in LMICs, specifically in response to the COVID-19 pandemic.

Vaccines and immunization

[edit]

Starting in 2010, PATH has collaborated with biotechnology and pharmaceutical companies to support the development of vaccines for diseases such as meningitis[17] and pneumonia and to help countries introduce vaccines for childhood illnesses such as rotavirus and Japanese encephalitis.

Meningitis

[edit]

PATH and the World Health Organization, through the Meningitis Vaccine Project, led the development of a vaccine called MenAfriVac to end meningitis A epidemics in sub-Saharan Africa, where 450 million people in 26 countries are at risk of the disease. The vaccine was developed by Serum Institute of India and introduced in Burkina Faso, Mali, and Niger in December 2010 to prevent the spread of a strain of meningitis found only in Africa. Within six months, the vaccine eliminated new cases of meningitis A in the areas where it was introduced.[17] By the end of 2012, the vaccine had reached 100 million people in ten countries: Benin, Burkina Faso, Cameroon, Chad, Ghana, Mali, Niger, Nigeria, Senegal, and Sudan.[18] The introduction of MenAfriVac marked the first time that a vaccine was developed for a disease only found in Africa.[19]

Previously used meningitis vaccines had low efficacy and cost USD $80 per dose. The new vaccine has high efficacy against the type of meningitis that is most prevalent in Africa and costs less than $0.50 per dose.[20] The entire vaccination research and development project cost less than US$100 million, about one-fifth the typical cost for developing a vaccine.[21]

In 2012, MenAfriVac was also approved for storage without refrigeration for up to four days, enabling health workers to more easily reach patients in rural villages or in areas with no power.[22]

Rotavirus

[edit]

PATH supports the introduction of vaccines against rotavirus in developing countries to protect young children from severe diarrhea. In 2006, PATH helped Nicaragua become the first developing country to introduce rotavirus vaccines within months of their introduction.[23] Former PATH researcher John Wecker noted that rotavirus infections dropped in areas that began to use the vaccine after the WHO recommended its international use in 2009.[24]

PATH also conducts research to show the impact of rotavirus vaccines and help countries choose whether to adopt the vaccines into their immunization programs.[25]

Japanese encephalitis

[edit]

PATH works in India and other countries in the region to introduce an affordable vaccine to protect against Japanese encephalitis—a disease the World Health Organization estimates claims 10,000 to 15,000 lives a year, mostly children, and causes permanent brain damage in many more.[26] In 2006, PATH helped the government of India launch an immunization campaign for children in high-risk areas with the vaccine.[27]

Epidemic diseases

[edit]

Part of PATH's work focuses on some of the most widespread and threatening global diseases: malaria, HIV/AIDS, tuberculosis, and influenza.

Malaria

[edit]

The PATH Malaria Vaccine Initiative supports several malaria vaccine candidates at various stages of development around the world, including the most advanced candidate, called RTS,S. Researchers studied RTS,S, made by GlaxoSmithKline, in phase 3 clinical trials among infants and young children in sub-Saharan Africa. A 2011 study showed the vaccine provided about 50 percent protection against malaria for young children ages 5 to 17 months, and another 2012 study showed a 33 percent reduction in infants.[28] In October 2013, GlaxoSmithKline reported that the experimental vaccine reduced the number of cases amongst young children by almost 50 percent and among infants by around 25 percent, following the conclusion of an 18-month clinical trial. GlaxoSmithKline is set to submit an application for a marketing license with the European Medicines Agency (EMA) in 2014. The new vaccine has the backing of the UN's Swiss-based WHO which states that it will recommend the use of RTS,S for use starting in 2015, providing it gets approval.[29]

Another PATH initiative to address malaria is the Malaria Control and Evaluation Partnership in Africa (MACEPA), which focuses on controlling malaria through the use of insecticide-treated bednets, indoor spraying of insecticides, new diagnostic tools to find infection, and effective medicines for treatment.[30] In Zambia, this work has helped decrease the rate of malaria among children younger than age 5 by 50 percent in two years.[30]

In December 2012, PATH received an award from the US President's Malaria Initiative for a new malaria project focused on "the expansion of high-quality diagnosis and treatment for malaria and other childhood illnesses and infectious diseases."[31]

PATH's Drug Development program, which grew out of an affiliation with OneWorld Health, is advancing a new, semisynthetic form of the malaria drug artemisinin that will bolster the current, volatile botanical supply.[32][33] In August 2014, PATH and Sanofi announced the release of the first batch of semisynthetic artemisinin. 1.7 million doses of Sanofi's ArteSunate AmodiaQuine Winthrop (ASAQ Winthrop), a fixed-dose artemisinin-based combination therapy will be shipped to half a dozen African countries over the next few months.[34]

HIV/AIDS

[edit]

PATH works in Africa, Asia, and other regions to slow the spread of HIV/AIDS and provide support for people affected by the disease. For example, in Kenya, PATH has conducted over two decades of research into HIV and pregnancy prevention.[35] PATH also provides support groups and health services for married adolescents and other groups at high risk for HIV.[36] It also aliases with local governments and community organizations to strengthen and expand services for HIV/AIDS, malaria, tuberculosis, and maternal and newborn health.[37]

Other PATH projects to address HIV in Africa include improving access to HIV treatment and services in Ethiopia[38] and expanding HIV counseling and testing and other services in the Democratic Republic of Congo.[39]

PATH uses behavior change communication techniques to encourage healthy behaviors for HIV prevention. One of the best-known examples is PATH's work with "magnet theater" in Kenya, India, Vietnam, and other developing countries. Named because of its natural pulling power, this interactive street theater draws people in rural communities to clearings, dirt roads, and village centers—any open space where people can gather. There, actors banter with their audiences and pull them into the play, stimulating dialogue about HIV/AIDS and other taboo subjects and helping individuals re-examine behaviors that contribute to poor health.

Maternal and child health

[edit]

In addition to its work on vaccines for childhood illnesses, PATH addresses pregnancy complications, nutrition issues, and other health challenges that affect women and children in developing countries and lead to higher rates of illness and death.

In 2012, PATH completed a seven-year project in India focused on safe birth for mothers and babies. PATH worked with local governments and community groups to encourage community leaders, health workers, pregnant women, and families to deliver babies in health centers, rather than at home, and adopt other best practices to protect mothers and their infants during pregnancy, childbirth, and infancy. The project used community outreach approaches including door-to-door clinical surveillance, distribution of printed health materials, and street theater to spread messages about maternal and newborn health.[40]

In South Africa, PATH leads a five-year project to improve the health and development of 750,000 pregnant women and children by encouraging breastfeeding and improving health care for pregnant women and young children.[41]

Funding and expenses

[edit]

PATH's income in 2020 was $303,223,000 and its expenses in 2020 were US$294,369,000. 86.4% of its budget was spent on program activities, 12.8% on administration, and .8% on fundraising.[3]

In 2010, PATH received the most US foundation grants in the state of Washington and ranked thirteenth among international recipients of US foundation grants.[42]

Controversies

[edit]

In 2012, the NGO was warned by the Indian government after one of its studies involving an HPV vaccine resulted in the alleged death of seven girls belonging to an indigenous community (tribe) in India.[43]

All 7 deaths were later attributed to other causes, including a snake bite, drowning, suicide by pesticide ingestion, and complications from malaria.[44]

In what The Hindu called "a shockingly unethical trial", nearly 2,800 consent forms were signed by a hostel warden or headmaster, as the 'guardian'.[45]

Recognition

[edit]

In 2003, PATH received the Tech Museum's Dr. Alejandro Zaffaroni Health Award for its work on the Uniject device, a sterile pre-filled, single-use syringe.[46]

Since 2005, PATH has remained on Forbes' top 200 list of the 200 largest charities in America.[47]

For five years running, Fast Company magazine in 2008 named PATH as one of the top social entrepreneurs who are changing the world.[48]

In 2009, PATH received the Conrad N. Hilton Humanitarian Prize.[49]

In 2012, PATH was ranked as the sixth best NGO in the world on the "top 100" list published by The Global Journal.[50]

As of March 2019, PATH has been vetted and is in good standing as part of GlobalGiving's GG Rewards program.[51]

See also

[edit]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

PATH (global health organization)

View on Grokipedia
from Grokipedia
PATH is an international founded in 1977 and headquartered in , dedicated to advancing in low- and middle-income countries through the development, adaptation, and implementation of innovative , diagnostics, devices, and health systems. With over 1,700 employees operating in more than 70 countries, PATH partners with governments, private sector entities, and philanthropies—primarily the Bill & Melinda Gates Foundation, which has provided substantial funding including a $120 million grant for its vaccine innovation center—to address challenges such as infectious diseases, , and . Among its notable achievements, PATH co-developed RTS,S/AS01, the world's first licensed , in collaboration with GlaxoSmithKline through its Malaria Vaccine Initiative, demonstrating approximately 30-50% efficacy against severe in African children during phase 3 trials. The organization has also pioneered technologies like intrauterine devices for and diagnostic tools for , contributing to broader interventions that have saved millions of lives indirectly through scaled innovations. PATH has encountered significant controversies, particularly regarding ethical standards in field projects; a prominent example is its 2009-2010 HPV vaccine demonstration initiative in , where an Indian parliamentary committee documented violations including inadequate , use of vulnerable tribal populations without proper oversight, and misrepresentation of the project as observational rather than experimental, amid reports of seven deaths among vaccinated girls that prompted suspension and calls for legal action.70420-0/fulltext) While PATH maintained the vaccines' safety was established and deaths unrelated, the incident highlighted risks of procedural lapses in trials conducted by Western NGOs in resource-limited settings.

History

Founding and Early Focus (1977–1990s)

PATH was established on May 12, 1977, in , by three family planning experts—Gordon Perkin, an obstetrician-gynecologist; Richard Mahoney, a contraceptive development specialist; and —as the Program for the Introduction and Adaptation of Contraceptive Technology (PIACT), later renamed PATH. 32758-6/fulltext) The initiative stemmed from a 1973 internal memo at their prior employer and received initial seed funding of $92,000 from the to pioneer "appropriate technologies" tailored for resource-limited settings in developing countries. From its inception with just three staff members, PATH emphasized practical innovations over high-cost Western models, focusing on adapting existing technologies for equitable access. In its formative years through the 1980s, PATH prioritized reproductive health and , developing and testing low-cost contraceptive methods and delivery systems, such as the Uniject prefilled syringe for injectable contraceptives, which simplified administration and reduced contamination risks in field settings. Early Ford Foundation-backed programs centered on tools, including educational materials and audiovisual aids to promote in rural and underserved areas of , , and . These efforts addressed barriers like inefficiencies and cultural resistance, with PATH conducting field trials to refine technologies for local manufacturing and distribution. By the late and into the , PATH began diversifying into technologies while maintaining its core reproductive health mandate, introducing vaccine vial monitors—thermochromic labels indicating heat exposure—to ensure efficacy during transport and storage in tropical climates; over 6 billion such monitors have been deployed worldwide since their rollout. The organization managed early projects in over 100 countries, partnering with governments and NGOs to integrate into primary health services, though its scope remained constrained by limited funding until external philanthropy increased in the mid-. This period solidified PATH's model of bridging research, adaptation, and implementation to combat high maternal and rates driven by unmet contraceptive needs.

Expansion into Vaccines and Epidemics (2000s)

During the 2000s, PATH broadened its scope beyond technology transfer and reproductive health to prioritize vaccine research, development, and deployment for neglected diseases, facilitated by substantial funding from the Bill & Melinda Gates Foundation and collaborations with international bodies. This shift addressed gaps in affordable vaccines for low- and middle-income countries, where epidemics and endemic threats like meningitis and malaria imposed heavy burdens. PATH's annual budget grew from approximately $60 million in 2000, reflecting increased investment in product development partnerships (PDPs) that integrated scientific innovation with market access strategies. A cornerstone of this expansion was the Malaria Vaccine Initiative (MVI), launched by PATH in 1999 with a $50 million Gates Foundation grant and advanced through a February 2000 agreement with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) to expedite candidate vaccines. MVI focused on pre-clinical and clinical-stage projects targeting , including support for GlaxoSmithKline's RTS,S , which entered Phase 3 trials by the late 2000s after PATH-WHO collaboration began in 2001. This effort marked PATH's entry into complex R&D pipelines, emphasizing transmission-blocking and blood-stage candidates to complement existing interventions. PATH's foray into epidemic response crystallized with the 2001 launch of the Meningitis Vaccine Project (MVP), a WHO-PATH partnership funded by a $70 million Gates grant to curb Group A Neisseria meningitidis epidemics in Africa's "meningitis belt." Building on 2000 discussions with the Epidemic Meningitis Vaccines for Africa initiative, MVP developed MenAfriVac, a low-cost conjugate vaccine manufactured by the Serum Institute of India, with Phase 2 trials starting in 2003 and demonstrating immunogenicity in endemic populations. By 2009, over 15 million doses were produced, enabling pilot introductions in Burkina Faso, Mali, and Niger, which interrupted seasonal outbreaks and informed broader epidemic preparedness. This project exemplified PATH's model of affordable innovation, achieving WHO prequalification in 2010 after technology transfer to local manufacturers. Parallel efforts included advancing (JE) vaccines for , where PATH identified the single-dose SA 14-14-2 strain (produced by China's Institute) as viable for global access due to its affordability and thermostability. From the early 2000s, PATH facilitated introductions in and , negotiating concessional pricing and supporting clinical data for WHO recommendation in 2006, contributing to reduced JE incidence in high-burden areas through routine integration. These initiatives underscored PATH's growing role in bridging R&D with deployment, though challenges like regulatory harmonization and vulnerabilities persisted.

Modern Era and Strategic Shifts (2010s–Present)

In the 2010s, PATH intensified efforts to scale vaccine access in low-resource settings, including the introduction and rollout of MenAfriVac, a meningococcal conjugate vaccine developed in partnership with the World Health Organization, which began immunization campaigns in Africa's "meningitis belt" in 2010 and averted an estimated 100,000 cases by 2015. The organization also advanced human papillomavirus (HPV) vaccine delivery models, supporting country-led introductions in over 20 low- and middle-income nations by mid-decade, emphasizing affordable procurement and cold-chain innovations to reach adolescent girls. Concurrently, PATH began shifting toward broader health systems strengthening, incorporating digital tools for supply chain management and data analytics, as evidenced by collaborations with the Bill & Melinda Gates Foundation to address barriers to scaling digital health interventions in developing countries. This period marked a strategic pivot from primarily product-focused to integrated implementation, with PATH launching the Innovation Countdown 2030 initiative in 2016 to prioritize 30 high-impact technologies addressing maternal, newborn, and child health needs, aiming to influence investment and policy for equitable adoption. By the late , emphasis grew on preparedness, including work on diagnostics and response tools, reflecting recognition of recurring outbreaks in fragile health systems. Funding from major philanthropies, such as the Gates Foundation, which has provided over $2 billion since PATH's , underpinned these expansions, though critics note potential alignment of priorities with donor agendas over purely endogenous needs. Entering the 2020s, PATH's response to the accelerated a focus on global equity, deploying expertise in partnerships and cold-chain to support initiatives and low-income country access, while advocating for to regional producers like those in and . In 2020, the organization formalized Strategy 2025, a five-year plan centering through cross-sector collaborations, data harnessing, and community-driven solutions across 70+ countries, with measurable goals like immunizing over 2 million children against via RTS,S integration. Recent efforts include platforms for monitoring in the of Congo and oxygen system scaling amid respiratory threats, signaling sustained integration of technology with frontline delivery to counter funding uncertainties in .

Organizational Structure and Operations

Mission, Strategy, and Approach

PATH's mission is to advance through and partnerships, with a focus on addressing the greatest health needs and challenges in underserved communities. This mission is guided by six core values: respect, which entails treating individuals with dignity and compassion; equity, aimed at eliminating barriers to ; , in upholding ethical actions; impact, by prioritizing solutions for pressing health issues; , through testing novel ideas and applying evidence; and , via cross-sector and cross-border partnerships. The organization's strategic framework is articulated in PATH Strategy 2025, launched in 2020 amid the COVID-19 pandemic and developed through consultations with over 400 stakeholders across 50 countries. This five-year plan responds to global health crises such as pandemics, antimicrobial resistance, and malaria, while aligning with local partner priorities to reimagine the role of international NGOs in fostering a more equitable sector. It emphasizes three interconnected priorities: preparing for and responding to emerging health threats; improving lives through science and technology, including vaccines, diagnostics, and medical devices; and enhancing health system capacity and resilience via tools like digital systems and improved access to essentials such as oxygen. PATH's approach integrates four change strategies—equity in health programming, respectful partnerships, community-focused priorities, and —supported by six enablers, including , diversity and inclusion efforts, , trusted relationships, operational , and advocacy. Operationally, this involves co-creating interventions with local stakeholders, developing scalable technologies (e.g., the RTS,S and NDV-HXP-S candidate), and building capacities in over 70 countries, such as policy support in , , and . The organization operates as a global team of innovators, prioritizing people-centered solutions that challenge health determinants, uphold , and elevate community-led design to accelerate equitable access and resilient systems.

Leadership and Global Presence

Nikolaj Gilbert serves as President and Chief Executive Officer of PATH, having assumed the role on January 6, 2020. Prior to this appointment, Gilbert held positions including director of global partnerships at the Office of Project Services and roles in the , bringing over 20 years of experience in and program innovation. The executive leadership team includes Nanthalile Mugala, MD, MMed, as Chief of the Region; Ben Aliwa as Chief Business and Finance Officer; Meïssa Diaw as Chief People Officer; and Nabeel Goheer, PhD, in a senior role overseeing operations. In 2024, PATH appointed Bilal Mateen, PhD, as its inaugural Chief AI Officer to direct the integration of into initiatives. PATH maintains headquarters in , Washington, which houses over 200 employees and underwent a relocation to a new facility in early 2024. The organization employs more than 3,000 staff globally and conducts operations across over 70 countries, with dedicated country offices and regional hubs in (e.g., Democratic Republic of Congo, , , , ), Asia (e.g., ), and the Americas (e.g., , , , , ). This decentralized structure facilitates partnerships with local governments, health systems, and communities to address region-specific health challenges.

Partnerships and Collaborations

PATH emphasizes multisector collaborations, integrating public institutions, private sector entities, businesses, social enterprises, and investors to accelerate health innovations and equity. These partnerships span product development, advocacy, and , often leveraging public-private models to bridge gaps and technical expertise in low-resource settings. A cornerstone of PATH's work involves funding and strategic alliances with major philanthropies, notably the Bill & Melinda Gates Foundation, which has provided significant grants for initiatives, such as a US$75 million award in the early 2000s to support development efforts aimed at preventing in children. PATH also collaborates within frameworks like the Vaccine Innovation Prioritisation Strategy (VIPS), partnering with Gavi, the Vaccine Alliance; the (WHO); ; and the Gates Foundation to prioritize and advance technologies for global access. In vaccine-specific collaborations, PATH has partnered with pharmaceutical companies like GlaxoSmithKline (GSK) to develop and advance the RTS,S through late-stage clinical trials and implementation in African research centers, culminating in WHO recommendations for its use. Similar efforts include and vaccine projects, often co-developed with industry partners to ensure affordability and scalability in developing countries. Beyond vaccines, PATH engages with multilateral organizations; for instance, a 2018 agreement with WHO focuses on transformation, while a 2023 memorandum with the (PAHO) targets in the through technology integration and policy support. Government partnerships form another pillar, exemplified by two decades of collaboration with Zambia's Ministry of Health since the early to scale innovative health approaches, including introduction and . In 2025, PATH launched a $120 million health-climate impact fund with the Global Innovation Fund to address climate-related health vulnerabilities, integrating data and innovation across sectors. These alliances prioritize mutual benefits, with PATH facilitating technology transfer and market shaping to sustain long-term impact, though outcomes depend on aligned incentives among partners.

Key Programs and Technologies

Vaccine and Immunization Initiatives

PATH's vaccine and immunization initiatives, primarily coordinated through its Center for Vaccine Innovation and Access (CVIA), emphasize accelerating the development, regulatory approval, and equitable delivery of vaccines targeting infectious diseases in low- and middle-income countries. These efforts involve partnerships with manufacturers, governments, and organizations like the (WHO) and , the Vaccine Alliance, to address vaccine supply chains, conduct clinical trials tailored to endemic settings, and support national immunization programs. CVIA's portfolio includes over two dozen vaccines across 17 disease targets as of 2019, focusing on late-stage development and access for priority pathogens. A cornerstone initiative is the Meningitis Vaccine Project (MVP), co-led by PATH and WHO from 2001 to 2016 in partnership with the Serum Institute of India. This effort developed MenAfriVac, a low-cost conjugate vaccine against Neisseria meningitidis serogroup A, launched in Burkina Faso in 2010 as the first campaign targeting the African "meningitis belt." By 2021, over 300 million doses had been administered across 26 at-risk countries, virtually eliminating serogroup A epidemics and reducing cases by more than 99% in vaccinated areas. Priced at approximately $0.50 per dose, MenAfriVac demonstrated the feasibility of affordable, heat-stable vaccines for resource-limited settings. Extending this success, PATH supported the development of MenFive, a pentavalent vaccine against serogroups A, C, W, Y, and X, prequalified by WHO in 2023 to broaden protection against remaining epidemic threats. In prevention, PATH's Rotavirus Vaccine Program (RVP), established in 2003 with $30 million from , bridged gaps in efficacy data for developing countries by funding trials in and , policy analyses, and delivery strategies. These activities facilitated WHO prequalification of oral vaccines Rotarix (2009) and RotaTeq (2010), enabling -supported introductions in over 40 countries by 2023. vaccination has averted an estimated 140,000 deaths annually from severe in children under 5, with global reductions of 59% in hospitalizations and 36% in all-cause deaths post-introduction. PATH's work highlighted programmatic innovations, such as integrating vaccines into routine schedules to improve coverage despite logistical challenges like cold-chain limitations. PATH advanced (JE) vaccination by adapting a Vero cell-based originally limited to for global use, achieving WHO prequalification in 2013 through and clinical bridging studies. In collaboration with partners, PATH supported rollout in endemic Asian regions, delivering over 220 million doses to children in six countries by 2017 and enabling national programs in 15 countries by 2023, immunizing more than 300 million at-risk individuals overall. This initiative reduced JE incidence by up to 90% in vaccinated cohorts, demonstrating effective cross-protection and supply chain enhancements for thermostable formulations. For malaria, PATH's Malaria Vaccine Initiative (MVI), launched in 1999 with Bill & Melinda Gates Foundation funding, partnered with GlaxoSmithKline (GSK) from 2001 to develop RTS,S/AS01 (Mosquirix), the first vaccine against Plasmodium falciparum. Phase 3 trials from 2009–2014 across seven African sites showed 36% efficacy against clinical and 56% against severe cases in young children after four doses. WHO recommended RTS,S in 2021 for routine use in sub-Saharan Africa's moderate-to-high transmission areas, following a 2019–2021 pilot in , , and that reached over 800,000 children and prevented approximately 13,900 hospitalizations. PATH continues to support scale-up, addressing durability challenges through co-administration with the RTS,S seasonal malaria chemoprevention.

Meningitis and Rotavirus Vaccines

PATH co-led the Vaccine Project (MVP), a partnership with the established in 2001 to develop an affordable against serogroup A , the predominant strain causing epidemics in sub-Saharan Africa's "meningitis belt." The project collaborated with the to produce MenAfriVac, a tailored for low-income settings, which received WHO prequalification in 2010 and was priced at approximately $0.50 per dose. By 2023, MenAfriVac campaigns had immunized over 300 million individuals across 26 countries in the meningitis belt, resulting in the near-elimination of serogroup A , with no confirmed cases reported in vaccinated areas since 2017. Building on MenAfriVac's success, PATH supported the development of MenFive, a pentavalent targeting serogroups A, C, W, X, and Y, manufactured by and prequalified by WHO in 2023 to address ongoing outbreaks from non-A strains. Clinical trials demonstrated MenFive's safety and immunogenicity in African infants, with phase 3 data from 2025 confirming protective responses comparable to licensed monovalent vaccines. PATH's role emphasized heat-stable formulations suitable for resource-limited logistics, contributing to broader control strategies aligned with WHO's Defeating Meningitis initiative. In efforts, PATH has advanced access and innovation since the early 2000s, partnering with pharmaceutical companies and WHO to facilitate the introduction of oral vaccines like Rotarix and RotaTeq in developing countries, where causes over 200,000 annual child deaths. These initiatives included clinical trials, improvements, and , leading to Gavi-supported rollout in low-income nations by 2016, which averted millions of diarrhea-related hospitalizations. PATH also coordinated RotaFlash, a 2011–2016 tracking global surveillance and efficacy data to inform national programs. To overcome limitations of oral vaccines—such as reduced efficacy in malnourished populations and cold-chain dependencies—PATH has led development of next-generation injectable candidates, including the trivalent P2-VP8 non-replicating vaccine targeting common strains. A phase 3 completed in October 2024 showed the injectable vaccine's noninferiority to oral Rotarix in preventing severe gastroenteritis among Malawian and Vietnamese infants, with topline efficacy data indicating potential for simplified delivery in low-resource settings. These efforts prioritize thermostable, needle-free options to enhance immunization coverage, with PATH emphasizing evidence from field trials over preclinical models.

Japanese Encephalitis and Other Childhood Vaccines

PATH collaborated with the Chengdu Biological Products Institute to advance the CD-JEV , a single-dose inactivated (JE) suitable for global use due to its affordability and ease of administration in resource-limited settings. This effort began in the early , focusing on research, regulatory support, and policy advocacy to facilitate introductions in JE-endemic regions of . By addressing manufacturing scale-up and prequalification processes with the (WHO), PATH enabled the vaccine's integration into national immunization programs. Through partnerships with , the Vaccine Alliance, and national health ministries, PATH supported JE vaccine introductions in 15 countries by 2023, protecting over 300 million children from this mosquito-borne flavivirus, which causes severe neurological disease with up to 30% fatality in symptomatic cases. Notable implementations include subnational rollout in , , in March 2018, targeting high-burden areas, and nationwide campaigns in starting around 2006. These efforts enhanced and addressed low-demand regions, contributing to JE incidence reductions of 73–100% in early-adopting countries within 5–20 years post-introduction. Beyond JE, PATH has advanced human papillomavirus (HPV) vaccines, targeting girls aged 9–14 to prevent , the leading cause of cancer deaths among women in low- and middle-income countries (LMICs). Initiatives include market shaping for affordable supply, demonstration projects, and integration into routine , such as school-based delivery in LMICs to overcome adolescent barriers. PATH's work facilitated HPV introductions in over 100 countries by 2023, emphasizing single- or two-dose regimens for higher coverage. PATH also supported typhoid conjugate vaccine (TCV) introductions for children in endemic areas, partnering on integrated campaigns combining TCV with , measles-rubella, and other antigens to reach zero-dose children efficiently. In , for instance, such efforts delivered multiple vaccines in a single outreach, improving equity and reducing Typhi transmission, which disproportionately affects children under 5. These programs emphasize cold-chain innovations and to sustain coverage against enteric fevers. Additionally, PATH provided technical assistance for campaigns, enhancing surveillance and delivery in high-risk settings to support global eradication goals.

Malaria and Epidemic Disease Vaccines

PATH established the Malaria Vaccine Initiative (MVI) in 1999 with an initial grant from the Bill & Melinda Gates Foundation to accelerate the development of vaccines and enable access in endemic countries. In 2001, PATH formed a public-private with GlaxoSmithKline (GSK) to advance the RTS,S/AS01 candidate vaccine, originally developed by GSK in 1987, through late-stage clinical testing in collaboration with African research centers. The Phase 3 , conducted from 2009 to 2014 across seven African countries involving 15,459 children, demonstrated that RTS,S reduced clinical episodes by 40% and severe cases by 30% over four years of follow-up. Following WHO recommendations for pilot implementation in 2016 and widespread use in 2021, along with prequalification in 2022, over 6 million doses have been administered since 2019, with pilots in , , and showing 13% fewer deaths and 22% fewer severe hospitalizations among vaccinated children. PATH continues to support RTS,S rollout and introduction in additional countries, reaching over 2 million children by facilitating , technical assistance, and efforts, such as youth-led campaigns in late 2024 and early 2025 to boost uptake. The organization also invests in next-generation vaccines to improve beyond RTS,S's modest protection levels, partnering with industry, academia, and funders like Foundation to target sporozoite and liver stages. In epidemic disease vaccines, PATH collaborates with the (CEPI) to develop countermeasures against high-threat pathogens, including , , , and others, supporting CEPI's goal of readiness within 100 days of an outbreak identification. For , PATH leads clinical development of candidates funded by a 2017 CEPI $25 million award to Profectus BioSciences, advancing a to Phase 1 trials in 2020 to assess safety and immunogenicity in humans, marking the first human testing of a Nipah-specific . PATH's roles in these efforts include , clinical oversight, innovation, and in low-resource settings to enable rapid deployment. Additionally, in 2025, CEPI allocated $8 million to PATH for developing "playbooks" mapping immune correlates of protection for priority epidemic threats, aiding faster evaluation.

Non-Vaccine Health Technologies

PATH advances non-vaccine health technologies through its platforms in devices, diagnostics, drugs, and system innovations, targeting barriers to health equity in low-resource settings. These efforts emphasize affordable, user-friendly tools to address maternal and child mortality, malnutrition, and environmental health risks, often via public-private partnerships that scale prototypes into market-ready solutions. For instance, PATH's Medical Devices and Health Technologies program develops devices specifically for women and children, focusing on reducing preventable deaths during pregnancy, childbirth, and early infancy.

Nutrition and Water/Sanitation Innovations

PATH's Innovation Initiative serves as an "idea incubator," integrating cross-sector solutions to tackle , including novel food technologies like cow-free alternatives and insect-based products aimed at sustainable, scalable dietary improvements in vulnerable populations. The organization also promotes newborn advancements, such as human banking with technologies, estimating that optimized practices could avert 823,000 annual child deaths globally. In water and sanitation, PATH's Safe Water Project, launched in late 2006 with $17 million in funding, pioneered market-based strategies to expand household and safe storage systems in and , addressing contamination risks that exacerbate diarrheal diseases. This initiative emphasized low-cost, consumer-preferred products like chlorine dispensers and filters, fostering private-sector supply chains to sustain access beyond donor support. PATH further integrates , , and hygiene (WASH) into broader systems strengthening, partnering with governments to generate evidence on service delivery in low-income contexts.

Sexual/Reproductive Health and Maternal/Child Tools

PATH prioritizes woman-centered contraceptive technologies, including the development of a one-year for long-acting, user-controlled , which reduces reliance on frequent visits and improves adherence in resource-limited areas. The organization's Reproductive Health program advances affordable supplies and innovations to enhance sexual and reproductive well-being, with field testing in multiple countries to ensure cultural and practical fit. For maternal and child health, PATH deploys diagnostic and monitoring devices such as next-generation pulse oximeters, which detect to guide timely interventions and potentially lower mortality rates in settings. Tools for Integrated Management of Childhood Illness include portable pulse oximeters and clinical decision support algorithms that process patient data for frontline workers, improving diagnostic accuracy without advanced infrastructure. Additional innovations encompass non-invasive screening biomarkers, reducing biohazards and enabling rapid assessment in surveys like Demographic and Health Surveys, and diagnostic aids like fever patches to curb maternal infections. Since 2012, PATH has piloted early childhood development interventions integrating health systems in countries including , , and , adapting tools for scalable family and community support. These technologies collectively aim to strengthen the continuum of care, with evaluations showing enhanced capabilities and reduced complications in labor and delivery.

Nutrition and Water/Sanitation Innovations

PATH's nutrition innovations center on large-scale to address deficiencies in staple foods, with a flagship technology being UltraRice®, extruded rice kernels fortified with iron, , , thiamin, niacin, , folic acid, and , designed for blending with conventional rice at ratios up to 1:100. Developed through PATH's technical advancements since 2002, including clinical trials, product testing, and supply chain protocols, UltraRice has been deployed in , , , , and , reaching 1 million consumers in alone and contributing to improved indicators in pilot areas. In , fortified rice using this technology was introduced for school feeding programs in March 2016, with PATH providing policy advocacy and quality assurance support. Complementing fortification efforts, PATH's Nutrition Innovation Initiative functions as a cross-sector incubator, integrating nutrition interventions into HIV services, maternal care, and agriculture programs while developing tools like nutritional impact assessments to evaluate agriculture investments' effects on dietary outcomes. These approaches emphasize evidence-based implementation, such as training health workers on nutrient access and promoting fortified staples to combat stunting and anemia in low-resource settings. In water innovations, PATH's Safe Water Project, active from 2006 to 2011, pioneered market-based strategies for household treatment and storage, targeting low-income households in , , , and through partnerships with institutions, retailers, and local entrepreneurs. The project tested and refined low-cost and chlorination technologies via over 600 hours of , yielding design guidelines and a commercialization toolkit that facilitated product scaling, ultimately serving more than 50,000 direct consumers and influencing manufacturer adaptations in . Building on this, PATH supported onsite chlorine generation devices like the system, which produces from salt and for health facilities in , , and , meeting intermediate-level disinfection standards to reduce infection risks. For sanitation, PATH has focused on user-informed, low-cost modular platforms that serve as adaptable sanitary barriers, compatible with squat or seated interfaces and designed for rapid assembly in urban low-income areas of and the region. These innovations incorporate community feedback to enhance aesthetic appeal and behavioral adoption, promoting decentralized dry systems that conserve , contain excreta, and enable for or via the . PATH's efforts extend to integrating , , and hygiene (WASH) in facilities, advocating for scalable solutions to curb diarrheal diseases linked to poor infrastructure.

Sexual/Reproductive Health and Maternal/Child Tools

PATH has developed the Woman's Condom, a next-generation featuring a thin, pliable pouch with a flexible outer ring for easier insertion and secure fit during intercourse, aimed at preventing and sexually transmitted infections including . Clinical trials demonstrated its safety and acceptability across diverse populations, with lower failure rates and fewer adverse events compared to the FC2 in short-term crossover studies involving users from the , , and . The device prioritizes user comfort and sensation, addressing barriers to adoption of earlier designs. In cervical cancer screening, PATH collaborated with Qiagen to create the careHPV test, a qualitative DNA assay detecting 14 high-risk HPV types in cervical or vaginal samples, optimized for low-resource clinics lacking reliable electricity or water. The test enables self-collection by women, yielding results in about 2.5 hours, and has shown superior sensitivity to visual inspection with acetic acid (VIA) and Pap smears for high-grade cervical intraepithelial neoplasia in rural settings. Developed with Bill & Melinda Gates Foundation support, it facilitates earlier detection in areas with limited infrastructure. For maternal and child health, PATH advances technologies to detect , a key indicator of complications like and , potentially reducing child mortality risk by 35% in high-burden settings through improved access. A 2022 PATH-Unitaid report highlights next-generation ' role in lowering maternal and child deaths by enabling rapid identification of low blood oxygen in resource-limited facilities. Through the Tools for Integrated Management of Childhood Illness (TIMCI) project, funded by Unitaid and led by PATH since 2019, accessible pulse oximeters and electronic clinical decision support algorithms (CDSAs) aid workers in triaging critically ill children under five, integrating with WHO protocols to enhance detection of severe illness without delaying care. Multi-country pilots in and , including and , demonstrated feasibility, with CDSAs processing vital signs data to guide referrals and reduce mortality from conditions like and . PATH also contributed to assessments of technologies for postpartum hemorrhage and management, prioritizing low-cost diagnostics for scale-up in low-resource environments via partnerships like Merck for Mothers.

Emerging Initiatives

In recent years, PATH has prioritized and integration of to address persistent challenges, with a focus on scalable, data-driven solutions. The organization's Digital Square initiative has spearheaded efforts to develop interoperable digital public goods, emphasizing and equity in low-resource settings. A prominent emerging effort is the Digital Public Infrastructure for Climate Health Resilience (DPI4CH), launched in 2024 and led by Digital Square with funding from the and the . This initiative aims to build resilient digital systems that link climate data—such as patterns and shifting vectors—with health , enabling predictive responses to climate-exacerbated risks like vector-borne illnesses. By December 2024, PATH announced expanded work to integrate global climate and health datasets, facilitating real-time analytics for decision-making in vulnerable regions. Complementing this, PATH released a guidebook annex on September 30, 2025, outlining trusted digital innovations for climate-resilient infrastructure, including tools for monitoring threats and adapting service delivery amid disasters. These projects underscore PATH's shift toward anticipatory systems, though empirical outcomes remain nascent, with implementation pilots ongoing in multiple countries. In parallel, PATH is exploring applications, such as large language models (LLMs) for , to assist frontline workers with diagnostics and treatment recommendations across diseases including . This includes LLM-enabled tools for interpreting complex data in resource-limited areas, though deployment is still in early stages as of 2025. For specifically, PATH's recent diagnostics-aligned work emphasizes integrated care models over standalone tools; for instance, in November and December 2024, projects in advanced person-centered HIV services by embedding TB and screening into primary systems, aiming to close gaps toward 2030 AIDS elimination targets.

HIV/AIDS and Diagnostic Tools

PATH's HIV/AIDS initiatives emphasize diagnostic innovations to enhance early detection and treatment adherence in low-resource settings, integrating screening tools with broader strengthening. Over 35 years, the organization has prioritized evidence-based technologies, such as improved HIV diagnostics, developed in collaboration with governments, private sector partners, and academics to address barriers like limited access and stigma. A key focus has been advancing HIV self-testing (HIVST) as an accessible diagnostic tool. In , PATH led a cross-sectional evaluation published on February 1, 2023, assessing four blood-based self-test kits—INSTI from bioLytical Laboratories (), SURE CHECK from Chembio Diagnostic Systems (), BioSURE from BioSure Ltd. (), and CheckNOW from Abbott Diagnostics ()—in . The study involved participants performing self-tests after brief training, yielding a 91% success rate in completion, high comparable to laboratory standards, and 94% willingness to use and recommend the kits at public-sector pricing. Partners included Ezintsha/Wits Health Consortium and the , with funding from the Bill & Melinda Gates Foundation and ; results supported policy advocacy for scaling HIVST to meet UNAIDS 95-95-95 targets by 2030, where 95% of people living with know their status. In , PATH's STAR Phase 3 project, concluded in June 2022, rolled out HIVST across 14 high-prevalence states using five delivery models tailored to key populations, including migrant workers and people who inject drugs. The initiative demonstrated high feasibility and acceptability, generating a summary report and compendium of success stories from sites in , , and , which informed national strategies to close testing gaps and achieve UNAIDS epidemic control goals by 2030. These efforts align with PATH's platform for devices and diagnostics, promoting point-of-need technologies to reduce diagnostic delays, though independent evaluations underscore the need for ongoing validation across HIV subtypes prevalent in diverse regions.

Recent AI and Climate-Health Projects (2024–2025)

In March 2025, PATH initiated a in , , to assess whether tools can enhance diagnostic quality by minimizing errors and omissions in settings. The trial focuses on large language models (LLMs) integrated into workflows for workers and clinicians, aiming to generate evidence on AI's efficacy in low-resource environments across . Complementing this, PATH began a parallel research trial in during 2024–2025 to evaluate generative AI as a knowledge assistant for workers, specifically testing its ability to support decisions and improve referrals. On the climate-health front, PATH launched the Digital Public Infrastructure for Climate Health Resilience (DPI4CH) initiative in 2024, funded by the and the , to develop interoperable digital tools that link data with systems for better forecasting of environmental risks like heatwaves and vector-borne diseases. In December 2024, PATH announced a data integration project to merge global and datasets, enabling for localized responses to hazards such as floods and droughts affecting vulnerable populations. Earlier in May 2025, PATH partnered with the Global Innovation Fund to establish a $120 million -climate impact fund, targeting innovations that mitigate climate-exacerbated burdens, including resilient supply chains for vaccines and diagnostics in at-risk regions. Intersecting AI with climate-health efforts, PATH collaborated on a 2024–2025 machine learning project to predict climate vulnerabilities for healthcare facilities and water sources, using algorithms to model risks from extreme weather events and inform adaptive infrastructure investments. Additionally, through the PATH Climate and Health Resilience Initiative (PATH-CHRI), supported by USAID, PATH advanced the Sustainable Action for Climate and Health program in 2024, emphasizing digital platforms to build community-level resilience against climate-driven epidemics. These projects underscore PATH's emphasis on evidence-based digital interventions, though independent evaluations of their long-term outcomes remain pending as of October 2025.

Funding and Financial Management

Primary Funding Sources and Donors

PATH's primary funding derives from philanthropic foundations and bilateral government agencies, with private foundations contributing the largest share. In 2023, foundations accounted for approximately $162 million in revenue, representing the dominant source, while U.S. government funding totaled about $115 million. These figures reflect PATH's reliance on restricted grants aligned with specific health innovation projects, such as vaccine development and diagnostic tools, rather than unrestricted operational support.
Revenue Source (2023, in thousands USD)Amount
Foundations161,651
U.S. Government114,966
The Bill & Melinda Gates Foundation stands out as PATH's single largest donor historically, providing over $1.46 billion since the early 2000s, including major grants like $241 million in 2017 for vaccine innovation and $120 million in the same year to advance global vaccination programs. Other significant foundations include , , and , each contributing multimillion-dollar grants in 2023 for initiatives in , , and technologies. Government and multilateral donors form a critical secondary pillar, with the U.S. Agency for International Development (USAID) channeling funds through bilateral aid for projects like epidemic preparedness and reproductive health tools. Entities such as , the Vaccine Alliance, the Global Fund to Fight AIDS, and Malaria, and the UK Foreign, Commonwealth & Development Office provided over $1 million each in 2023, often tied to vaccine rollout and supply chain enhancements in low-income countries. Corporate donors, including , Merck, and , supplement these with in-kind contributions and grants exceeding $1 million, primarily supporting pharmaceutical access and clinical trials. This donor composition underscores PATH's project-specific funding model, where over 85% of expenses directly support programs, though it also highlights vulnerability to fluctuations in philanthropic priorities.

Revenue, Expenses, and Efficiency Metrics

In fiscal year 2023, PATH reported total revenue of $352.7 million, with contributions from foundations accounting for $161.7 million (46%), the U.S. government for $115.0 million (33%), other governments, NGOs, and multilaterals for $52.6 million (15%), corporations for $11.0 million (3%), investments for $10.1 million (3%), and individuals/other sources for $2.4 million (1%). Total expenses reached $351.8 million, yielding a net surplus of approximately $0.9 million. Expenses were categorized with $318.6 million (90.6%) allocated to program-related activities, including $95.8 million for programs and innovation, $46.4 million for , $40.4 million for operations, $34.8 million for , , and , $93.3 million in subawards to partners, and smaller amounts for program development and other regional efforts. Administrative costs totaled $31.6 million (9.0%), while fundraising expenses were minimal at $1.5 million (0.4%). PATH maintains high , directing over 85% of spending to programs and less than 2% to , as self-reported. Independent evaluation by confirms a program expense ratio of 89.97% for 2023, with efficiency at $0.01 spent per dollar raised, contributing to an overall three-star rating (80/100 score). In 2024, preliminary revenue indicators show continued growth, with foundations contributing $168.6 million and the U.S. $128.2 million, though full audited figures remain pending consolidation.
Fiscal YearTotal Revenue ($M)Total Expenses ($M)Program Expenses (%)Fundraising Expenses (%)
2023352.7351.890.60.4

Dependency on Government and Philanthropic Aid

PATH's operational funding is predominantly derived from provided by philanthropic foundations and agencies, reflecting its nonprofit model focused on developing and distributing technologies for low- and middle-income countries rather than commercial revenue generation. In 2023, contributions and accounted for approximately 98% of , with negligible from program services or asset . This structure underscores a high degree of reliance on external aid, as PATH does not generate substantial self-sustaining through product or licensing, prioritizing public-sector delivery over market-driven returns. A detailed breakdown of 2023 revenue reveals foundations contributing 45.8% ($161.7 million), primarily from the Bill & Melinda Gates Foundation as the largest single philanthropic donor; the U.S. government providing 32.6% ($115.0 million), largely via USAID; and other governments, nongovernmental organizations, and multilaterals accounting for 14.9% ($52.6 million), including entities like , the Vaccine Alliance, and the Global Fund. Together, philanthropic and government sources comprised over 90% of funding, with total revenue reaching $352.7 million and expenses at $351.8 million. This concentration exposes PATH to donor-specific priorities and budgetary shifts, as evidenced by partnerships emphasizing collaborative grants over diversified revenue streams. The organization's dependency has manifested in vulnerabilities to policy changes, such as a U.S. funding freeze in early under the incoming administration, which prompted PATH to affirm operational continuity while highlighting risks to ongoing projects amid reduced bilateral aid. Philanthropic backers like the Gates Foundation, while significant, have indicated limitations in offsetting large-scale government aid reductions, potentially straining PATH's capacity for long-term initiatives in vaccine development and systems strengthening. Such reliance aligns with broader trends in nonprofits, where grant dependency ensures alignment with donor goals but amplifies susceptibility to geopolitical and fiscal fluctuations.

Impact Assessments

Claimed Achievements and Metrics

PATH reports reaching an average of 150 million people annually through its health innovations and programs over its history. In 2024, the claimed to have improved healthcare access for 34.8 million individuals—equivalent to 66 lives per minute—across more than 70 countries via over 350 active projects and support to 332 local partners. These efforts encompassed vaccine delivery, diagnostic tools, and maternal-child health interventions, with PATH asserting contributions to elimination campaigns in and and technical assistance in humanitarian crises. Among specific product milestones, PATH highlights the widespread adoption of its vaccine vial monitors, with over 6 billion units deployed globally to verify vaccine viability during transport and storage, thereby preventing spoilage in low-resource settings. For vaccines, the organization claims involvement in the MenAfriVac rollout, which reached over 262 million Africans since its introduction, and the campaigns protecting more than 232 million people, primarily children, in Asia. Additional metrics include the Sure Start project in serving 24.5 million individuals with nutrition and health services, and nearly 500,000 doses of the Sayana Press injectable contraceptive administered to expand access. In clinical research, PATH's 2024 report states it initiated 5 trials—all registered with WHO or ClinicalTrials.gov—and achieved full compliance in publishing peer-reviewed results for all eligible completed studies within required timelines. Earlier, in 2023, similar trial initiation and reporting standards were maintained across 380 active projects, including support for vaccinating millions of children against typhoid, polio, and malaria, though exact vaccination figures were not quantified in the report. These self-reported figures underscore PATH's emphasis on scalable technologies, but independent verification of attribution for broader health outcomes remains limited in the organization's disclosures.

Empirical Evaluations and Limitations

Independent clinical trials of PATH-supported vaccine candidates have provided empirical evidence of efficacy, though with notable limitations in scale, duration, and generalizability. For instance, the RTS,S/AS01 , advanced through PATH's collaboration with GlaxoSmithKline and others, was evaluated in a Phase 3 trial across 11 sites in seven African countries involving 15,459 children aged 5-17 months. The trial reported a 56% reduction in episodes of clinical in the first year post-vaccination, declining to 36% over 48 months with a , and a 30% reduction in severe . However, efficacy waned significantly after the booster, and the prevented only about four severe cases per 100 vaccinated children over four years, highlighting incomplete protection against transmission. Post-introduction evaluations of RTS,S pilots in , , and , supported by PATH's technical assistance, have assessed real-world implementation. A standardized across these sites found vaccination coverage reaching 70-90% in routine programs, with no significant safety signals beyond , but identified challenges in integrating the four-dose schedule into existing systems, leading to dropout rates of 20-30%. GiveWell's cost-effectiveness modeling of PATH's support estimates 1-2 lives saved per 3,000−3,000-5,000 in technical assistance , based on averting 0.1-0.2 deaths per vaccinated, yet these projections incorporate uncertainties such as variable transmission intensity and potential resistance development. Independent modeling by WHO and partners similarly projects 40-50% reductions in in high-burden areas over a decade, but stresses that benefits depend on achieving >80% coverage, which pilots have not consistently met due to and equity gaps. Broader limitations in PATH's empirical evaluations stem from reliance on project-specific metrics rather than organization-wide longitudinal studies, complicating attribution of outcomes to PATH's interventions amid multifaceted aid ecosystems. Many assessments, including PATH-coordinated ones, face toward high-profile , underrepresenting diagnostics or tools where impact data is sparser or less rigorous. For example, while PATH's introductions in low-income countries correlated with reduced cervical precancer rates in observational studies, is confounded by concurrent screening expansions and varying baseline prevalence. concerns arise from dependency on external donors; recent U.S. pauses in led to 45% reductions, potentially disrupting ongoing evaluations and scaling. Charity Navigator's analysis rates PATH's overall effectiveness at 80%, citing strong program spending (82% of expenses) but moderate evidence depth due to limited randomized controlled trials beyond and potential overestimation of indirect benefits like . These factors underscore the need for more randomized, long-term studies to validate claimed multipliers, such as PATH's assertion of averting millions of deaths through innovations, against counterfactual scenarios without their involvement.

Long-Term Sustainability Questions

PATH's funding model, characterized by heavy reliance on grants from a small number of large philanthropic and governmental donors, raises questions about its ability to sustain operations amid fluctuating aid landscapes. Major supporters in 2023 included the Bill & Melinda Gates Foundation and the United States Agency for International Development (USAID), which provided substantial restricted funding for specific projects, limiting PATH's flexibility to reallocate resources during shortfalls. This donor concentration—typical of nonprofits—exposes PATH to risks from policy changes or priority shifts, as evidenced by the 2025 U.S. funding freeze under the incoming administration, which disrupted federal aid flows and prompted PATH to affirm its commitment to continuity despite uncertainties. Despite efficient , with approximately 85% of expenses directed toward program services and less than 2% on , PATH's remains predominantly grant-dependent, lacking significant diversification through earned , endowments, or widespread individual contributions. Independent assessments, such as Charity Navigator's three-star rating (80% score), commend accountability and transparency but note room for enhanced , which could bolster donor confidence and mitigate funding volatility. In the broader context of nonprofit , such grant reliance fosters path dependency, where organizations become vulnerable to donor-driven agendas rather than self-sustaining models, potentially hindering adaptability to long-term needs. Sustainability concerns extend to PATH's project-based approach, where interventions often cease upon grant expiration, prompting inquiries into whether the can transition to enduring, locally financed systems or if repeated funding cycles perpetuate external dependency without building organizational reserves. Recent sector analyses highlight that entities like PATH, operating in low-margin environments, face amplified risks from geopolitical shifts and donor fatigue, as seen in reduced U.S. commitments, underscoring the need for strategies to cultivate alternative amid uncertain philanthropic trajectories. While PATH's track record of supports short-term viability, the absence of public strategies for diversification or contingency reserves fuels debate over its resilience beyond the next funding cycle.

Controversies and Criticisms

Ethical Issues in Clinical Trials (e.g., 2012 HPV Study)

In 2009, PATH, in collaboration with the Indian Council of Medical Research (ICMR) and state health departments, initiated a human papillomavirus (HPV) vaccine demonstration project in the states of Andhra Pradesh and Gujarat, administering vaccines to approximately 24,000 girls aged 10–14 years, with around 7,000 receiving a placebo or no vaccine as controls. The project, funded primarily by the Bill & Melinda Gates Foundation with a budget exceeding $2 million, aimed to assess the feasibility, acceptability, and delivery logistics of HPV vaccines—Merck's Gardasil and GlaxoSmithKline's Cervarix—in public health systems rather than to test vaccine efficacy or safety, as both products were already licensed by India's Drug Controller General. However, the initiative faced suspension by the Indian government in April 2010 following reports of seven deaths among vaccinated girls, sparking investigations into potential ethical lapses. Key ethical concerns centered on informed consent procedures, which were deemed inadequate by a 2013 Indian Parliamentary Standing Committee report (72nd Report on the Department of Health Research). Consent forms were often obtained from school wardens or headmasters rather than parents or guardians, with many illiterate participants or families not fully comprehending the risks, benefits, or experimental nature of the project; the report documented instances where girls as young as 10 signed forms themselves, violating ICMR ethical guidelines requiring parental involvement for minors. The committee highlighted targeting of vulnerable tribal and low-income communities in remote areas, raising coercion allegations, as participation was linked to school attendance without clear opt-out mechanisms or independent oversight. Ethics committee approvals were criticized for conflicts of interest, with some members having ties to vaccine manufacturers, and the project proceeded without a full clinical trials registry entry, blurring lines between and trial. Regarding the deaths—five in and two in —post-mortem examinations attributed causes to unrelated factors such as , , , and , with no direct vaccine causality established by government probes or WHO reviews. Nonetheless, the parliamentary report faulted PATH and partners for insufficient adverse event monitoring and follow-up, including delayed reporting of serious events, which eroded trust and amplified perceptions of negligence. PATH responded by asserting the adhered to local regulations at and was not a safety or efficacy trial, emphasizing that global data supported safety, but acknowledged process shortcomings and committed to enhanced guidelines. The controversy prompted petitions, leading to 2013 guidelines mandating stricter , vulnerability assessments, and compensation for trial injuries, influencing national drug regulations under the Drugs and Cosmetics Rules. Critics, including the committee, argued the episode exemplified how international NGOs like PATH could prioritize donor-driven agendas over local ethical standards, potentially exploiting regulatory gaps in developing countries for data generation benefiting Western markets. PATH's involvement in similar projects elsewhere has since incorporated these lessons, though the Indian case underscores ongoing tensions in trials between innovation imperatives and participant protections.

Undermining Local Health Systems

Critics have argued that PATH's implementation of health interventions, particularly its 2009 demonstration project in India, bypassed established national regulatory and ethical frameworks, thereby eroding the authority and operational capacity of local health authorities. The project, conducted in partnership with the (ICMR) in and , involved administering HPV vaccines to approximately 23,000 adolescent girls without obtaining necessary approvals from the (DCGI), instead relying on a questionable "observational" designation that masked its trial-like nature. This approach, as detailed in the Indian Parliament's 72nd Standing Committee on Health and Family Welfare Report released on August 30, 2013, violated national laws and ethical guidelines, including requirements for and regulatory oversight, and recommended legal action against PATH for exporting "dubious" trials to vulnerable populations while circumventing safeguards. Such bypassing not only exposed participants to unmonitored risks— with seven deaths and adverse events reported amid inadequate follow-up mechanisms— but also strained local health infrastructure by diverting administrative resources toward managing external projects rather than bolstering indigenous systems. The committee noted that PATH exerted undue influence on ICMR and state governments to integrate HPV vaccines into the (UIP) without rigorous cost-effectiveness analyses or phase III trial data tailored to Indian demographics, potentially prioritizing donor-funded pharmaceutical interests (from partners like Merck and GlaxoSmithKline) over sustainable public sector priorities. This pattern fostered perceptions of foreign NGOs supplanting government roles, weakening incentives for local in vaccine evaluation and procurement. Broader critiques extend to PATH's model of introducing technology-driven interventions in low-resource settings, which some contend creates parallel delivery structures that fail to integrate with or strengthen existing networks. In resource-constrained environments, reliance on externally managed projects can discourage investment in foundational local capabilities, such as training workers or enhancing within national systems, leading to episodic aid rather than enduring self-sufficiency. While PATH maintains partnerships aim to build resilience, the Indian case illustrates how expedited, donor-aligned initiatives may inadvertently undermine regulatory independence and , complicating long-term ownership by host governments.

Broader Concerns on Aid Dependency and Tech Push

Critics of global health organizations like PATH contend that their heavy emphasis on donor-funded technological interventions fosters aid dependency in recipient countries, as these initiatives often prioritize short-term deployment of innovations over building enduring local capacities. For example, PATH's work in vaccines and diagnostics, supported by major funders such as the Bill & Melinda Gates Foundation and USAID, introduces advanced tools that require ongoing external supply chains, training, and maintenance, potentially locking low-income nations into reliance on foreign aid rather than developing self-reliant systems. This dynamic aligns with broader analyses of development aid, where vertical programs—focused on specific diseases or technologies—displace investments in horizontal health infrastructure, such as primary care networks and workforce training, thereby perpetuating cycles of intervention without addressing root causes of underdevelopment. The technological push by PATH, exemplified in efforts to accelerate for new devices and biologics in over 70 countries, raises concerns about appropriateness and in resource-constrained settings. While PATH employs to adapt innovations, empirical evaluations suggest that high-tech solutions from wealthier contexts frequently encounter barriers like inadequate , leading to underutilization or abandonment once funding wanes. In , for instance, PATH's involvement in demonstration projects from 2009 onward drew scrutiny from a Parliamentary Standing Committee report, which highlighted how such externally driven initiatives sidelined cost-effective practices and contributed to fragmented service delivery, undermining government-led systems. Although PATH has pursued local partnerships, such as supporting African firms in production since the early and diagnostics assembly to reduce import dependency, these measures are viewed by some as insufficient to counter the inherent path dependencies created by aid models. Donors' focus on measurable outputs—like coverage metrics—often incentivizes tech-centric projects that yield quick wins but fail to cultivate fiscal and institutional self-sufficiency, as evidenced in financing critiques where aid volumes exceed domestic health budgets in many low-income countries. This approach risks entrenching inequities, as countries remain vulnerable to fluctuations in international funding, such as the 2025 U.S. aid pauses that disrupted PATH's operations and highlighted the fragility of donor-dependent ecosystems.

References

  1. https://www.path.org/who-we-are/
  2. https://www.path.org/who-we-are/faq/
  3. https://philanthropynewsdigest.org/news/gates-foundation-awards-120-million-to-path-for-vaccine-initiative
  4. https://www.path.org/our-impact/articles/path-40-years-of-innovation-and-impact/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC9773038/
  6. https://www.path.org/our-impact/media-center/rtss-malaria-candidate-vaccine-reduces-malaria-by-approximately-one-third-in-african-infants/
  7. https://www.nature.com/articles/nindia.2013.122
  8. https://www.science.org/content/article/indian-parliament-comes-down-hard-cervical-cancer-trial
  9. https://www.path.org/our-impact/media-center/statement-from-path-hpv-demonstration-project-in-india/
  10. https://www.bmj.com/content/347/bmj.f5492
  11. https://www.lifesciencehistory.com/path-was-founded/
  12. https://rockarch.issuelab.org/resources/30313/30313.pdf
  13. https://www.hiltonfoundation.org/laureates/path/
  14. https://www.gatesfoundation.org/ideas/media-center/press-releases/1999/04/program-for-appropriate-technology-in-health-path
  15. https://www.seattletimes.com/seattle-news/obituaries/gordon-perkin-a-giant-in-public-health-who-helped-shape-the-gates-foundation-dies/
  16. https://www.path.org/files/RMER_timeline.pdf
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4639496/
  18. https://www.sciencedaily.com/releases/2000/02/000214101246.htm
  19. https://www.who.int/news-room/questions-and-answers/item/malaria-vaccine-implementation-programme
  20. https://www.path.org/our-impact/articles/about-meningitis-vaccine-project/
  21. https://pubmed.ncbi.nlm.nih.gov/17521780/
  22. https://www.path.org/our-impact/articles/how-once-little-used-vaccine-now-protects-millions-japanese-encephalitis/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC8206071/
  24. https://media.path.org/documents/ER_annual_report_2010.pdf
  25. https://www.path.org/our-impact/
  26. https://www.path.org/publications/files/TS_dhs_journey_to_scale.pdf
  27. https://media.path.org/documents/Reimagining_Global_Health.pdf
  28. https://www.path.org/who-we-are/programs/center-for-vaccine-innovation-and-access/path-strives-vaccine-equity-response-covid-19/
  29. https://www.path.org/who-we-are/annual-report-2023/strategy/
  30. https://onlinelibrary.wiley.com/doi/10.1002/jia2.26112
  31. https://www.path.org/who-we-are/mission-and-strategy/
  32. https://media.path.org/documents/PATH-Strategy-2025.pdf
  33. https://www.path.org/our-impact/media-center/path-names-mr-nikolaj-gilbert-president-and-ceo/
  34. https://theorg.com/org/path-org/org-chart/nikolaj-gilbert
  35. https://www.geekwire.com/2019/tech-moves-path-taps-nikolaj-gilbert-new-ceo-concur-co-founder-steve-singh-joins-clari-board/
  36. https://www.path.org/who-we-are/annual-report-2024/leadership/
  37. https://www.path.org/our-impact/media-center/path-appoints-dr-bilal-mateen-as-inaugural-chief-ai-officer/
  38. https://www.geekwire.com/2024/global-health-nonprofit-path-moving-to-new-hq-space-in-seattle-that-was-once-home-to-tableau/
  39. https://www.geekwire.com/2025/seattle-global-health-nonprofit-path-cutting-workforce-after-federal-funding-freeze/
  40. https://www.path.org/where-we-work/
  41. https://www.path.org/get_involved/global-partners/
  42. https://www.ghtcoalition.org/members-items/path
  43. https://www.path.org/our-impact/resources/public-private-partnerships-for-global-health-how-path-advances-technologies-through-cross-sector-collaboration/
  44. https://www.path.org/our-impact/media-center/path-launches-new-vaccine-development-effort-to-prevent-pneumonia-save-a-million-children-a-year/
  45. https://www.gavi.org/our-alliance/market-shaping/vaccine-innovation-prioritisation-strategy-vips
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC8222942/
  47. https://www.path.org/our-impact/case-studies/developing-the-worlds-first-malaria-vaccine-rtss/
  48. https://www.path.org/our-impact/articles/partnerships-make-our-vaccine-work-possible/
  49. https://www.path.org/our-impact/media-center/who-and-path-partner-globalize-digital-health/
  50. https://www.path.org/our-impact/resources/a-compendium-of-successes-celebrating-two-decades-of-impactful-partnership-between-path-and-the-ministry-of-health-in-zambia/
  51. https://www.globalinnovation.fund/news/thrive/gif-partners-with-path-to-launch-a-new-health-climate-fund
  52. https://www.path.org/our-impact/resources/public-private-partnerships-for-global-health-paths-collaborations-with-european-partners/
  53. https://www.path.org/who-we-are/programs/center-for-vaccine-innovation-and-access/
  54. https://www.researchgate.net/figure/PATHs-Center-for-Vaccine-Innovation-and-Access-spectrum-of-projects-legend-PATH_fig2_342087685
  55. https://www.joghr.org/article/29042-implementation-of-the-meningitis-vaccine-project-in-africa-lessons-for-vaccine-implementation-programs
  56. https://www.path.org/our-impact/articles/a-new-vaccine-could-stop-meningitis-epidemics-in-africafor-good/
  57. https://www.defeatdd.org/blog/research-and-relationships-define-20-years-rotavirus-vaccines-1/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC10839819/
  59. https://www.gavi.org/vaccineswork/how-rotavirus-vaccines-are-changing-game
  60. https://dcvmn.org/wp-content/uploads/2017/05/path_introduction20170429.pdf
  61. https://www.malariavaccine.org/existing-vaccines/rtss
  62. https://www.gavi.org/vaccineswork/how-africa-defeated-meningitis
  63. https://info.path.org/e/961212/140-673628252900046-7-abstract/6s31q/523842441/h/K46ULly2VHGS9y9FSTsAMLHHAsLRPt5Gtb40eeJrPec
  64. https://academic.oup.com/cid/article/62/suppl_2/S91/2478845
  65. https://www.path.org/who-we-are/programs/center-for-vaccine-innovation-and-access/rotaflash/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC9699535/
  67. https://www.path.org/our-impact/media-center/path-shares-topline-results-from-a-phase-3-study-of-an-injectable-rotavirus-vaccine-candidate/
  68. https://www.gavi.org/vaccineswork/injectable-rotavirus-vaccines-what-value-could-they-bring
  69. https://www.nature.com/articles/s41541-021-00338-z
  70. https://www.path.org/edging-out-je/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC9154647/
  72. https://www.facebook.com/PATHglobalhealth/photos/after-20-years-of-global-and-local-partnerships-15-countries-have-introduced-jap/727866856050726/
  73. https://www.path.org/edging-out-je/approaching-vaccination-from-end-to-end/lesson-1-meet-countries-where-they-are/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC11398676/
  75. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012390
  76. https://www.path.org/who-we-are/programs/center-for-vaccine-innovation-and-access/accelerating-hpv-vaccine-access/
  77. https://www.path.org/our-impact/articles/how-one-path-project-advanced-the-global-hpv-prevention-landscape/
  78. https://immunizationeconomics.org/recent-activity/2023/11/22/new-findings-from-a-path-study-on-the-cost-and-operational-context-of-hpv-vaccine-delivery-in-six-countries/
  79. https://www.givewell.org/research/grants/path-technical-assistance-to-support-malaria-vaccines-rollout-march-2024
  80. https://media.path.org/documents/CVP_Global.pdf
  81. https://www.gatesfoundation.org/ideas/articles/typhoid-hpv-vaccines-children
  82. https://www.path.org/our-impact/resources/the-path-malaria-vaccine-initiative/
  83. https://www.path.org/our-impact/articles/turning-trust-into-coverage-youth-led-efforts-raise-malaria-vaccine-uptake/
  84. https://www.path.org/our-impact/media-center/cepi-and-path-strengthen-partnership-to-accelerate-development-of-vaccines-against-diseases-with-epidemic-or-pandemic-potential/
  85. https://www.emergentbiosolutions.com/press/news-release-details-cepi-awards-25-million-contract-profectus-biosciences-and-0/
  86. https://www.path.org/our-impact/articles/nipah-virus-film-contagion-vaccine/
  87. https://cepi.net/rd-experts-create-playbooks-map-immune-markers-deadly-diseases-0
  88. https://www.path.org/who-we-are/programs/mdht/
  89. https://www.path.org/our-impact/resources/nutrition-innovation-new-approaches-to-combat-malnutrition-and-improve-health/
  90. https://www.path.org/who-we-are/programs/maternal-newborn-child-health-and-nutrition/
  91. https://www.gsb.stanford.edu/faculty-research/case-studies/path-safe-water-project-improving-access-safe-water-through-innovative
  92. https://www.path.org/who-we-are/programs/market-dynamics/safe-water-project/
  93. https://mwawater.org/millennium-water-alliance-welcomes-path-as-newest-member/
  94. https://www.path.org/what-we-do/health-and-disease-management/sexual-and-reproductive-health/
  95. https://www.path.org/who-we-are/programs/reproductive-health/
  96. https://unitaid.org/news-blog/next-generation-pulse-oximeters-have-great-potential-to-reduce-maternal-and-child-mortality-path-and-unitaid-report-says/
  97. https://www.path.org/who-we-are/programs/market-dynamics/timci/
  98. https://www.path.org/what-we-do/health-and-disease-management/maternal-newborn-and-child-health/
  99. https://www.path.org/our-impact/case-studies/advancing-large-scale-food-fortification-to-improve-nutrition/
  100. https://www.path.org/publications/files/ER_nutrition_fs.pdf
  101. https://www.path.org/our-impact/resources/introduction-of-a-novel-chlorine-generator-in-ghana-uganda-and-ethiopia-public-health-systems/
  102. https://media.path.org/documents/TS_swp_sanitation.pdf
  103. https://www.path.org/our-impact/articles/supporting-safe-water-sanitation-and-hygiene-health-care-facilities/
  104. https://www.path.org/our-impact/resources/womans-condom-comfortable-and-confident-protection-for-women-and-men/
  105. https://pubmed.ncbi.nlm.nih.gov/19014792/
  106. https://www.contraceptionjournal.org/article/S0010-7824%2808%2900403-4/pdf
  107. https://www.path.org/our-impact/articles/carehpv-test/
  108. https://www.path.org/our-impact/media-center/path-announces-new-cervical-cancer-test-for-low-resource-countries/
  109. https://www.sciencedirect.com/science/article/abs/pii/S0301211514001389
  110. https://www.hpvworld.com/articles/the-carehpv-test/
  111. https://www.path.org/who-we-are/programs/advocacy-and-policy/oxygen-therapy-newborn-child-and-maternal-health/
  112. https://www.path.org/our-impact/media-center/next-generation-pulse-oximeters-have-great-potential-to-reduce-maternal-and-child-mortality-path-and-unitaid-report-says/
  113. https://unitaid.org/project/better-tools-to-detect-danger-signs-in-children/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC11060010/
  115. https://www.path.org/our-impact/articles/accelerating-appropriate-technologies-maternal-health/
  116. https://pubmed.ncbi.nlm.nih.gov/24405972/
  117. https://www.path.org/who-we-are/programs/digital-health/digital-square/
  118. https://www.path.org/who-we-are/programs/digital-health/digital-public-infrastructure-for-climate-health-resilience/
  119. https://www.rockefellerfoundation.org/news/new-path-initiative-to-integrate-global-climate-and-health-data/
  120. https://www.path.org/our-impact/articles/harnessing-trusted-digital-innovation-for-climate-resilient-digital-public-health-infrastructure-a-new-global-goods-guidebook-annex/
  121. https://www.path.org/who-we-are/programs/digital-health/large-language-models-for-health-equity/
  122. https://www.path.org/who-we-are/programs/hiv-aids-tuberculosis/
  123. https://www.path.org/who-we-are/programs/hiv-aids-tuberculosis/about/
  124. https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0001438
  125. https://www.path.org/our-impact/media-center/path-led-evaluation-of-four-hiv-diagnostic-products-helps-advance-hiv-self-testing-efforts/
  126. https://media.path.org/documents/20220925_1215_hrs_Final_Summary_Report_HIVST_India.pdf
  127. https://www.path.org/our-impact/resources/hiv-self-testing-/
  128. https://www.path.org/our-impact/media-center/path-launches-artifical-intelligence-clinical-trial/
  129. https://www.geekwire.com/2025/path-launches-landmark-ai-study-in-africa-exploring-llms-potential-in-health-diagnoses/
  130. https://www.path.org/our-impact/media-center/new-study-examines-how-generative-ai-can-assist-community-health-workers-in-rwanda/
  131. https://heathealth.info/news/over-2-billion-in-cities-will-be-exposed-to-0-5oc-rise-by-2040-2/
  132. https://www.engr.washington.edu/industry/capstone-projects/2024-2025/path/using-machine-learning-to-predict-climate-risk-to-healthcare-facilities-and-water-sources
  133. https://www.path.org/our-impact/resources/promoting-climatehealth-resilience/
  134. https://www.path.org/our-impact/articles/can-ai-improve-health-care-delivery-in-africa-5-things-you-should-know/
  135. https://www.path.org/who-we-are/annual-report-2023/financial-summary/
  136. https://donations.vipulnaik.com/donee.php?donee=PATH
  137. https://www.geekwire.com/2017/path-receives-120m-gates-foundation-grant-fuel-vaccine-development-across-globe/
  138. https://www.path.org/who-we-are/annual-report-2023/supporters/
  139. https://www.path.org/who-we-are/finances/
  140. https://www.charitynavigator.org/ein/911157127
  141. https://www.path.org/who-we-are/annual-report-2024/financial-summary/
  142. https://projects.propublica.org/nonprofits/organizations/911157127
  143. https://media.path.org/documents/PATH-annual-report-2023.pdf
  144. https://www.path.org/our-impact/resources/usaid-and-path-working-together-to-improve-global-health/
  145. https://www.geekwire.com/2025/we-will-go-on-global-health-nonprofit-path-navigates-u-s-funding-freeze-from-new-seattle-hq/
  146. https://www.nytimes.com/2025/02/22/health/usaid-who-trump-china.html
  147. https://www.devex.com/news/money-matters-who-got-gates-health-funding-in-2023-106912
  148. https://www.path.org/who-we-are/annual-report-2024/
  149. https://www.path.org/who-we-are/annual-report-2023/
  150. https://www.nejm.org/doi/full/10.1056/NEJMoa1208394
  151. https://pmc.ncbi.nlm.nih.gov/articles/PMC10052308/
  152. https://www.givewell.org/research/grants/PATH-malaria-vaccines-January-2022
  153. https://cdn.who.int/media/docs/default-source/immunization/sage/vpp-background-documents/malaria/path_final-report-on-vaccine-impact-and-cost-effectiveness-estimates6d0e5362-c947-4ff8-b0d5-1c485c0ed8ce.pdf?sfvrsn=371c20a_1
  154. https://philanthropynewsdigest.org/news/path-receives-17-million-from-gates-foundation-for-clean-drinking-water
  155. https://www.philanthropyroundtable.org/the-price-of-dependence-nonprofits-and-government-funding/
  156. https://www.path.org/l/sustainable-integrated-health-services/
  157. https://www.cgdev.org/blog/26-countries-are-most-vulnerable-us-global-health-aid-cuts-can-other-funders-bridge-gap
  158. https://hsrii.org/wp-content/uploads/2014/07/72.pdf
  159. https://www.ecchr.eu/fileadmin/Fallbeschreibungen/Case_Summary__Clinical_Trials__2014-02-11.pdf
  160. https://ijme.in/articles/trials-and-tribulations-an-expose-of-the-hpv-vaccine-trials-by-the-72nd-parliamentary-standing-committee-report/?galley=html
  161. https://www.hhrjournal.org/2014/11/06/health-rights-litigation-pushes-for-accountability-in-clinical-trials-in-india/
  162. https://www.qmul.ac.uk/media/news/2012/smd/controversial-vaccine-trial-should-never-have-been-run-in-india-researchers-say.html
  163. https://www.nature.com/articles/nature.2013.13700
  164. https://www.linkedin.com/pulse/how-ngos-like-path-undermined-indias-government-health-dvzfc
  165. https://www.path.org/our-impact/media-center/statement-from-path-cervical-cancer-demonstration-project-in-india/
  166. https://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-015-0090-3
  167. https://insight.kellogg.northwestern.edu/article/international-aid-development-ngos-crowding-out-government
  168. https://www.path.org/what-we-do/health-systems-strengthening/
  169. https://pubmed.ncbi.nlm.nih.gov/18404650/
  170. https://www.path.org/our-impact/articles/investment-insights-local-manufacturing-diagnostic/
  171. https://www.path.org/our-impact/articles/supporting-vaccine-manufacturers-supply-critical-vaccines/
  172. https://globalizationandhealth.biomedcentral.com/articles/10.1186/s12992-023-00999-6
  173. https://pmc.ncbi.nlm.nih.gov/articles/PMC12036835/
Add your contribution
Related Hubs
User Avatar
No comments yet.